Bydur-Eon - the monthly extended exenatide?
This article was originally published in Scrip
Executive Summary
Amylin and Eli Lilly have conducted a 121-patient, Phase II dose-ranging study of a once-monthly suspension formulation of exenatide in development. The new formulation consists of extended-release microspheres of Bydureon (exenatide once weekly) with a triclyceride-based diluent that enables delivery of higher doses with lower frequency.